(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 0.26% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Organon & Co's revenue in 2025 is $6,281,000,000.On average, 2 Wall Street analysts forecast OGN's revenue for 2025 to be $1,637,788,347,012, with the lowest OGN revenue forecast at $1,633,056,973,474, and the highest OGN revenue forecast at $1,642,519,720,549. On average, 3 Wall Street analysts forecast OGN's revenue for 2026 to be $1,635,952,990,024, with the lowest OGN revenue forecast at $1,594,888,827,165, and the highest OGN revenue forecast at $1,665,765,842,624.
In 2027, OGN is forecast to generate $1,651,756,297,571 in revenue, with the lowest revenue forecast at $1,598,060,407,229 and the highest revenue forecast at $1,697,148,887,320.